.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,242,147

« Back to Dashboard

Details for Patent: 8,242,147

Title:Aryl ureas with angiogenisis inhibiting activity
Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Inventor(s): Dumas; Jacques (Bethany, CT), Scott; William J. (Guilford, CT), Elting; James (Madison, CT), Hatoum-Makdad; Holia (Hamden, CT)
Assignee: Bayer Healthcare LLC (Tarrytown, NY)
Filing Date:Sep 23, 2010
Application Number:12/888,887
Claims:1. A method for treating a condition in a human and/or other mammal which is ischemic retinal-vein occlusion or age related macular degeneration, comprising administering to a human or other mammal in need thereof an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea of the formula below or a pharmaceutically acceptable salt thereof ##STR00012##

2. A method as in claim 1 wherein N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea or a pharmaceutically acceptable salt thereof is administered simultaneously with another angiogenesis inhibiting agent to a patient in need thereof in the same formulation or in separate formulations.

3. A method for treating age related macular degeneration comprising administering to a human or other mammal in need thereof an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbam- oyl)-4-pyridyloxy)phenyl) urea of the formula below or a pharmaceutically acceptable salt thereof ##STR00013##

4. A method as in claim 1 wherein the disease that is treated is ischemic retinal-vein occlusion or age related macular degeneration, in combination with an infectious disease selected from the group consisting of: tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-like toxin resulting from E. coli infection, effects of enterotoxin A resulting from Staphylococcus infection, meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV).

5. A method as in claim 3 comprising administering the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea tosylate.

6. A method as in claim 1 comprising administering the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea tosylate.

7. A method for treating ischemic retinal-vein occlusion comprising administering to a human or other mammal in need thereof an effective amount of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbam- oyl)-4-pyridyloxy)phenyl) urea of the formula below or a pharmaceutically acceptable salt thereof ##STR00014##

8. A method as in claim 7 comprising administering the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl) urea tosylate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc